NIVABUPA
Niva Bupa Health Insurance Company Limited
Each stock's 10,000-path forecast, rendered as light.
Niva Bupa Health Insurance Company Limited (NIVABUPA) Stock Analysis & Case Study
Is NIVABUPA a good buy? The data-driven verdict.
Niva Bupa Health Insurance Company Limited (NIVABUPA) trades at ₹86,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Niva Bupa Health Insurance Company Limited (NIVABUPA) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 91.5× earnings, ROE of 3.5%, a 55% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
NIVABUPA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How NIVABUPA ranks against the 2,373 companies in our screener
- NIVABUPA's market cap of 15,939 Cr ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NIVABUPA's book value of ₹21 ranks in the 19th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NIVABUPA's promoter holding of 55.3% ranks in the 42nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NIVABUPA's 3-year profit (PAT) growth of 127.0% ranks in the top 4% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NIVABUPA's 3-year revenue growth of 33.0% ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NIVABUPA's debt-to-equity ratio of 0.07x is lower than 82% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is NIVABUPA overvalued? NIVABUPA P/E vs peers
NIVABUPA trades at 91.5× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
NIVABUPA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 1.7y of NIVABUPA history (9%/yr drift, 36%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| NIVABUPA 2027 | ₹56 | ₹90 | ₹144 | +5% |
| NIVABUPA 2028 | ₹50 | ₹94 | ₹179 | +9% |
| NIVABUPA 2029 | ₹44 | ₹99 | ₹219 | +14% |
| NIVABUPA 2030 | ₹41 | ₹103 | ₹260 | +19% |
| NIVABUPA 2031 | ₹38 | ₹108 | ₹304 | +25% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability NIVABUPA goes up, or doubles?
The bull case for NIVABUPA
- Niva Bupa Health Insurance Company Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹219.
The bear case & risks
- NIVABUPA's P/E of 91.5x is lower than 12% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- NIVABUPA's return on equity of 3.5% ranks in the 24th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹44.
NIVABUPA volatility & expected range, how bumpy is the ride?
Over the last 1.7 years NIVABUPA compounded at 9%/year with annualized volatility of 36%. That volatility implies a 1-year 80% range of ₹56-₹144, the honest backbone behind any single price target.
NIVABUPA price forecast, the full 60-month probability fan
NIVABUPA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds NIVABUPA hits common targets within the simulated horizon?
Full multi-horizon detail on the NIVABUPA price target & forecast page.
NIVABUPA Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. NIVABUPA scores 5/8, mixed financial health.
NIVABUPA MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy NIVABUPA with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 28.44% | 3.5× |
| ZerodhaCHEAPEST | 28.42% | 3.5× |
| Groww | 28.54% | 3.5× |
| DhanCHEAPEST | 28.42% | 3.5× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 28.66% | 3.5× |
| Pocketful | 28.76% | 3.5× |
| Anand RathiCHEAPEST | 28.42% | 3.5× |
| Bajaj Broking | 32.00% | 3.1× |
| Share India | 28.52% | 3.5× |
Compare every broker on the NIVABUPA MTF page.
About Niva Bupa Health Insurance Company Limited: sector, index & market-cap context
Niva Bupa Health Insurance Company Limited (NIVABUPA) is a small-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹15,939 Cr. See more stocks on our screener.
How the NIVABUPA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Niva Bupa Health Insurance Company Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
NIVABUPA analysis, FAQs
Is Niva Bupa Health Insurance Company Limited (NIVABUPA) a good buy?
On the numbers, Niva Bupa Health Insurance Company Limited (NIVABUPA) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 91.5× earnings, ROE of 3.5%, a 55% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is NIVABUPA overvalued or undervalued?
NIVABUPA trades at 91.5× earnings, expensive versus the ~22× long-run Nifty average.
What is the NIVABUPA share price target for 2031?
NIVABUPA's probability-weighted 2031 median target is ₹108, with an 80% range of ₹38-₹304 (10,000-path Monte-Carlo).
What is the probability NIVABUPA doubles in 5 years?
The modelled probability of NIVABUPA reaching ₹172 (2×) within 5 years is 28%.
What is the bull case for NIVABUPA?
Niva Bupa Health Insurance Company Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in NIVABUPA?
NIVABUPA's P/E of 91.5x is lower than 12% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. NIVABUPA's return on equity of 3.5% ranks in the 24th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.